AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$TNGX

Crystal Adam sold $618K of TNGX

Crystal Adam (President, R&D) sold 27,000 shares of Tango Therapeutics, Inc. (TNGX) at an average of $22.87 ($22.25–$23.06, $0.62M total) across 2 trades on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Crystal Adam
Published Jun 3, 2026, 10:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TNGX
Bearish
medium confidence
Mentioned
$TNGX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TNGXBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, which can influence short‑term price action.

02

Market read

First‑report insider sale for Tango Therapeutics, modest size, may affect short‑term trading sentiment.

03

What to watch

Potential upcoming clinical data releases could offset the negative signal.

Relevance 4/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions required by regulators.

Company-level read

Ticker impact

$TNGXBearishMedium confidence
Context

President of R&D sold 27,000 shares for $617.5K via a 10b5-1 plan, reducing holdings to 115,743 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A senior R&D officer sold a sizable block under a pre‑arranged plan, which traders often view as a negative signal.

Market effects

Sector

Minimal impact on biotech sector; isolated insider transaction.

Regional

No regional effect.

Global

Limited to investors tracking Tango Therapeutics.

Counterpoint

What could challenge this read

The sale was pre‑arranged under a 10b5‑1 plan, so it may not reflect current sentiment.

Key entities

  • Insider
    Crystal Adam

    President, R&D at Tango Therapeutics

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TNGX insider trading history →

Related articles

SEP 3
$TNGXMedAI 8/10

Tangram Therapeutics PLC: Tangram Therapeutics Announces Progression to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial of TGM-312 and Appointment of Dr Sonya Montgomery as Chief Development Officer

Tangram Therapeutics announced its MASH treatment TGM-312 has progressed to patient cohorts in a Phase 1/2 trial. The company also appointed Dr. Sonya Montgomery as Chief Development Officer. TGM-312 targets liver inflammation and steatosis, with interim data expected in 2027. Dr. Montgomery brings 25 years of experience in clinical development.

finanznachrichten.de2 min
AUG 11
$TNGXMed

Why is Tango Therapeutics stock sliding today?

Tango Therapeutics (TNGX) shares fell about 4% to $26.58 after Q2 2026 results missed expectations. Net loss widened to $0.37 per share versus $0.35 a year earlier, above the ~$0.32 consensus. The quarter again had zero revenue. General and administrative expenses nearly doubled to $22.6M from $11.3M, driven by personnel and share-based comp.

investing.com4 min
AUG 11
$TNGXMed

Tango Therapeutics Reports Second Quarter 2026 Financial Results

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 da

SEC EDGAR 8-K4 min
JUL 15
$TNGXMed

Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues

Canaccord Genuity raised its price target for Tango Therapeutics (NASDAQ:TNGX) to $46 from $42 and kept a Buy rating, citing a revised model that includes combined revenues from vopimetostat plus KRAS inhibitors in NSCLC. Jefferies upgraded TNGX to Buy and lifted its target to $60. Tango also signed an underwriting for about 18.2M shares plus pre-funded warrants, expecting ~$566.5M net proceeds for trials and R&D.

yahoo.com5 min